NZ515913A - Modified chimeric polypeptides with improved pharmacokinetic properties - Google Patents

Modified chimeric polypeptides with improved pharmacokinetic properties

Info

Publication number
NZ515913A
NZ515913A NZ515913A NZ51591300A NZ515913A NZ 515913 A NZ515913 A NZ 515913A NZ 515913 A NZ515913 A NZ 515913A NZ 51591300 A NZ51591300 A NZ 51591300A NZ 515913 A NZ515913 A NZ 515913A
Authority
NZ
New Zealand
Prior art keywords
fusion polypeptide
nucleotide sequence
vegf receptor
nucleic acid
acid molecule
Prior art date
Application number
NZ515913A
Other languages
English (en)
Inventor
Nicholas J Papadopoulos
Samuel Davis
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ515913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NZ515913A publication Critical patent/NZ515913A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
NZ515913A 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties NZ515913A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
PCT/US2000/014142 WO2000075319A1 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Publications (1)

Publication Number Publication Date
NZ515913A true NZ515913A (en) 2004-01-30

Family

ID=22480568

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515913A NZ515913A (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Country Status (32)

Country Link
EP (2) EP1183353B1 (https=)
JP (2) JP4723140B2 (https=)
KR (1) KR100659477B1 (https=)
CN (3) CN100523187C (https=)
AT (2) ATE293164T1 (https=)
AU (2) AU779303B2 (https=)
BE (1) BE2013C029I2 (https=)
BR (2) BRPI0011407B8 (https=)
CA (1) CA2376379C (https=)
CY (2) CY1108883T1 (https=)
CZ (2) CZ303656B6 (https=)
DE (2) DE60019415T2 (https=)
DK (2) DK1544299T3 (https=)
ES (2) ES2319305T3 (https=)
FR (1) FR13C0028I2 (https=)
HR (1) HRP20010908B1 (https=)
HU (3) HU230159B1 (https=)
IL (3) IL146890A0 (https=)
LT (1) LTC1183353I2 (https=)
LU (1) LU92195I2 (https=)
ME (2) ME00024B (https=)
MX (1) MXPA01012630A (https=)
NO (4) NO330775B1 (https=)
NZ (1) NZ515913A (https=)
PL (1) PL208247B1 (https=)
PT (2) PT1183353E (https=)
RS (1) RS50073B (https=)
RU (1) RU2265661C2 (https=)
SK (1) SK287332B6 (https=)
UA (1) UA74146C2 (https=)
WO (1) WO2000075319A1 (https=)
ZA (1) ZA200110068B (https=)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
EP1353952B1 (en) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
EP2301564A1 (en) 2002-05-04 2011-03-30 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US7052691B2 (en) * 2003-03-28 2006-05-30 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking VEGF-mediated activity
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP3514238B1 (en) 2003-05-16 2021-05-05 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
AU2004242586C1 (en) * 2003-05-28 2011-02-24 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using VEGF antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1631317A2 (en) * 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CA2534197A1 (en) * 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy
US8226941B2 (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
KR100897379B1 (ko) * 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
EP1753442A2 (en) 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
MXPA06014689A (es) * 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
US7378095B2 (en) 2004-07-30 2008-05-27 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
DK2229956T3 (da) 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
DK1962895T3 (da) † 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
US20140080153A1 (en) * 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
KR20260004598A (ko) 2011-01-13 2026-01-08 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
BR112014013205A2 (pt) 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
HUE046134T2 (hu) 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
CA2927012A1 (en) 2013-11-05 2015-05-14 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
PT3230316T (pt) 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017087798A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
CN108290004A (zh) 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
CA3005132A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Coated syringe for ophthalmic formulations containing a vegf antagonist
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
PT3384049T (pt) 2015-12-03 2023-08-18 Regeneron Pharma Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
WO2018070390A1 (ja) 2016-10-12 2018-04-19 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
DK3668985T3 (da) 2017-08-17 2021-09-20 Just Evotec Biologics Inc Fremgangsmåde til rensning af glycosyleret protein fra værtscellegalectiner og andre urenheder
CA3081094A1 (en) 2017-11-20 2019-05-23 Alison J. GILLESPIE Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
DK3717636T5 (da) * 2017-11-27 2024-08-26 4D Molecular Therapeutics Inc Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese
EP4122486A1 (en) 2017-11-30 2023-01-25 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat diabetic retinopathy
IL296138B2 (en) * 2017-12-13 2024-11-01 Regeneron Pharma Devices and systems for chromatography column bed support management and related methods
KR102742284B1 (ko) 2017-12-22 2024-12-16 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
WO2020229584A1 (en) 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
MX2022002355A (es) 2019-09-03 2022-04-06 Amgen Inc Dispositivo de inyeccion para suministro de farmacos y envase para el dispositivo de inyeccion.
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
AU2020397053A1 (en) 2019-12-06 2022-06-23 Regeneron Pharmaceuticals, Inc. VEGF mini-traps and methods of use thereof
US11180540B2 (en) 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
EP4110427A1 (en) 2020-02-24 2023-01-04 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
EP4438629A1 (en) 2021-11-24 2024-10-02 Suzhou Light Ferry Biomed. Co., Ltd Multispecific ligand binding molecule and application thereof
WO2024029876A1 (ko) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도
CN119584953A (zh) 2022-09-16 2025-03-07 齐鲁制药有限公司 一种稳定的高浓度自缓冲药物组合物
AU2024322540A1 (en) * 2023-08-04 2026-03-05 Panolos Bioscience, Inc. Conjugate of modified fusion protein and scfv, and use thereof
WO2025213011A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Method of assessing stopper movement in a drug delivery device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
DK1183353T3 (da) 2005-08-08
UA74146C2 (uk) 2005-11-15
CZ302689B6 (cs) 2011-09-07
CY1108883T1 (el) 2014-07-02
SK287332B6 (sk) 2010-07-07
NO20016036D0 (no) 2001-12-10
CN101433715A (zh) 2009-05-20
NO2013010I2 (no) 2013-05-15
BE2013C029I2 (https=) 2019-03-06
DE60019415D1 (de) 2005-05-19
SK17522001A3 (sk) 2003-04-01
HK1132653A1 (en) 2010-03-05
ES2319305T3 (es) 2009-05-06
EP1544299A1 (en) 2005-06-22
RS50073B (sr) 2009-01-22
HRP20010908B1 (en) 2006-05-31
HK1185798A1 (en) 2014-02-28
RU2265661C2 (ru) 2005-12-10
AU779303B2 (en) 2005-01-13
BRPI0011407B1 (pt) 2018-09-25
LU92195I2 (fr) 2013-07-15
AU2005201365A1 (en) 2005-04-28
HU230159B1 (hu) 2015-09-28
CY2013019I1 (el) 2015-11-04
WO2000075319A1 (en) 2000-12-14
HU229156B1 (en) 2013-09-30
EP1544299B1 (en) 2008-12-17
NO20100656L (no) 2002-02-08
HK1043388A1 (en) 2002-09-13
ME00024B (me) 2010-02-10
CA2376379C (en) 2007-08-07
AU5040400A (en) 2000-12-28
NO330775B1 (no) 2011-07-11
HUP0201515A2 (en) 2002-08-28
NO20016036L (no) 2002-02-08
HUP0201515A3 (en) 2004-12-28
HRP20010908A2 (en) 2005-04-30
CZ303656B6 (cs) 2013-01-30
IL146890A (en) 2008-07-08
ATE417928T1 (de) 2009-01-15
HUS1300052I1 (hu) 2016-08-29
MXPA01012630A (es) 2002-07-22
CN103349781B (zh) 2015-04-01
LTC1183353I2 (lt) 2023-02-27
KR20020019070A (ko) 2002-03-09
JP4723140B2 (ja) 2011-07-13
CZ20014387A3 (cs) 2002-10-16
IL146890A0 (en) 2002-08-14
DE60041159D1 (de) 2009-01-29
IL190234A0 (en) 2008-11-03
AU2005201365B2 (en) 2007-08-09
PT1544299E (pt) 2009-03-18
CN103349781A (zh) 2013-10-16
CN1369009A (zh) 2002-09-11
JP2003501089A (ja) 2003-01-14
YU86901A (sh) 2004-05-12
ATE293164T1 (de) 2005-04-15
FR13C0028I2 (fr) 2014-05-16
NO332559B1 (no) 2012-10-29
ZA200110068B (en) 2002-12-06
JP2011024595A (ja) 2011-02-10
EP1183353B1 (en) 2005-04-13
CN100523187C (zh) 2009-08-05
EP1183353A1 (en) 2002-03-06
KR100659477B1 (ko) 2006-12-20
CN101433715B (zh) 2013-04-17
PT1183353E (pt) 2005-06-30
ES2237429T3 (es) 2005-08-01
BRPI0011407B8 (pt) 2021-05-25
JP5273746B2 (ja) 2013-08-28
DK1544299T3 (da) 2009-03-23
DE60019415T2 (de) 2006-03-09
FR13C0028I1 (fr) 2013-06-14
BR0011407A (pt) 2002-04-02
LTPA2013009I1 (lt) 2013-06-25
PL352246A1 (en) 2003-08-11
NO2022060I1 (no) 2022-12-21
MEP3208A (xx) 2010-02-10
PL208247B1 (pl) 2011-04-29
CY2013019I2 (el) 2015-11-04
CA2376379A1 (en) 2000-12-14
NO2013010I1 (no) 2013-06-17

Similar Documents

Publication Publication Date Title
NZ515913A (en) Modified chimeric polypeptides with improved pharmacokinetic properties
DE69837884D1 (de) Erbb4 rezeptor-spezifisches neuregulin, verwandte liganden und deren verwendungen
Nilsson et al. Competitive elution of protein A fusion proteins allows specific recovery under mild conditions
AU1846995A (en) Heterologous g protein coupled receptors expressed in yeast, their fusion with g proteins and use thereof in bioassay
KR960704038A (ko) 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)
CA2502385A1 (en) Il-1 receptor based antagonists and methods of making and using
ATE393222T1 (de) Dcr3 polypeptid, ein tnfr homolog
PT100379A (pt) Bibliotecas de receptores heterodimericos usando fagomideos
WO2001007611A3 (en) Novel polynucleotides and method for the use thereof
KR20120095837A (ko) Crm197 및 그 유도체의 제조를 위한 합성 유전자의 박테리아성 발현
WO1999063088A3 (en) Membrane-bound proteins and nucleic acids encoding the same
CA2318482A1 (en) Il-18 receptors
JP2003506008A5 (https=)
NO940736L (no) DNA sekvenser som koder for gelonin polypeptid
US7037684B2 (en) Process for producing polypeptide having disulfide bond
KR930008147A (ko) 화학 화합물의 생합성적 제조방법
Legros et al. Influence of a NH2‐terminal extension on the activity of KTX2, a K+ channel blocker purified from Androctonus australis scorpion venom
WO2001098453A3 (fr) Vecteurs d'expression comprenant un fragment modifie de l'operon tryptophane
WO2001029224A3 (en) Granulocyte peptide homolog zgpa1
WO1990007000A3 (en) Nucleotides encoding human b1, 4-galactosyltransferase and uses thereof
KR850006703A (ko) 재조합체 dna 발현 벡터의 제조방법
IE62522B1 (en) A process for the preparation of foreign proteins in streptomycetes
WO2005017162A3 (en) Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
KR100451432B1 (ko) Ｔ-20 펩타이드의 생물학적 제조방법
JP5020487B2 (ja) 融合タンパク質発現用新規ｄｎａ及び該ｄｎａを用いたタンパク質の製造方法

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 23 MAY 2020 BY ANDY BREEDEN

Effective date: 20130529

EXPY Patent expired